Kodiak Sciences, Inc. (KOD)

Kodiak Sciences' stock experienced significant movements in the past six months. In August 2025, senior management presented the company's pipeline programs in glaucoma. In November 2025, the company anticipated significant milestones in 2026, including unveiling topline data and submitting its BLA. In December 2025, Kodiak Sciences completed a public offering of common stock, raising $184 million, and the stock hit a 52-week high. In January 2026, the company presented at the J.P. Morgan Healthcare Conference, and analysts updated their ratings. In February 2026, Kodiak Sciences announced final Phase 1b results for KSI-101, and the company's shares surged, with the average one-year price target revised to $31.33 per share.

Kodiak Sciences Inc. is a precommercial, clinical-stage biopharmaceutical company with no approved products on the market and generates no revenue from product sales. Therefore, there is no demand seasonality for Kodiak Sciences' products and services at this time.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases, such as wet AMD, DME, and DR. The company's ABC Platform aims to create durable, disease-modifying treatments. Key product candidates include Tarcocimab tedromer (KSI-301), KSI-501, and KSI-101, all in Phase 3 clinical trials. As a precommercial company, Kodiak Sciences currently does not have any approved products and is yet to generate revenues.

Kodiak Sciences Inc. is headquartered in Palo Alto, California, United States. The company conducts its clinical trials primarily in the United States, with additional international sites to support global patient enrollment.

Kodiak Sciences' brand reputation is tied to its clinical development programs and scientific rigor. Positive clinical trial results have contributed to a positive sentiment among investors and analysts. The company's commitment to scientific innovation and patient-centric approaches forms the core of its professional standing.

Kodiak Sciences Inc. has a significant institutional ownership presence. 254 institutional owners and shareholders hold a total of 47,363,881 shares. Major institutional owners include Baker Bros. Advisors Lp, BlackRock, Inc., Point72 Asset Management, L.P., and Vanguard Group Inc. Institutional ownership accounts for approximately 44.79% of shares outstanding, while individuals/insiders hold around 4.70%.